Table 1 Demographic characteristics of the studies included
From: Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus
Study/year | Location | Treatment arm (n) | Sex (male/female) | Duration of follow-up (months) | Age (years) | Duration of diabetes (years) | BMI (kg/m2) | HbA1c (%) | MMSE score (0[worst]-30[best]) |
|---|---|---|---|---|---|---|---|---|---|
Isik,2017 [36] | Turkey | sita: 43 met: 69 insu: 22 | sita: 47/57 met + insu: 35/66 | 6 | 77.05 ± 8.50 77.12 ± 7.87 77.61 ± 9.40 | 13.38 ± 8.5 12.95 ± 4.99 15.66 ± 6.97 | 28.86 ± 4.21 29.78 ± 4.71 28.33 ± 5.24 | 7.29 ± 1.49 6.90 ± 1.29 7.50 ± 1.19 | 22.73 ± 5.64 23.55 ± 5.38 23.50 ± 4.03 |
Borzi,2019 [37] | Italy | vild + met: 30 met: 30 | vild + met: 14/16 met:13/17 | 6 | 77.67 ± 8.23 75.46 ± 7.89 | 16.72 ± 5.81 15.49 ± 6.83 | 29.55 ± 5.92 28.48 ± 6.69 | 8.02 ± 1.27 7.09 ± 1.21 | 21.00 ± 1.41 20.77 ± 1.22 |
Biessels,2019 [38] | Netherland | lina: 800 pla: 745 | lina: 503/297 pla: 501/244 | 30 | 67.8 ± 8.3 67.7 ± 8.0 | 14.8 ± 9.2 15.4 ± 9.4 | 32.5 ± 5.1 32.8 ± 5.3 | 7.8 ± 0.9 7.8 ± 0.9 | 28.3 ± 1.7 28.2 ± 1.8 |
Xue, 2020 [39] | China | dpp4i: 30 sulfo: 30 | dpp4i: 17/13 sulfo: 14/16 | 6 | 68.5 ± 7.1 67.4 ± 5.9 | 8.17 ± 3.05 8.97 ± 2.65 | 25.71 ± 3.76 25.59 ± 4.28 | 8.56 ± 1.25 8.86 ± 3.17 | 25.42 ± 1.22 25.37 ± 1.16 |
Bulut,2020 [40] | Turkey | vild: 43 pla: 35 con: 52 | vild: 18/25 pla + con: 20/32 | 6 | 74.4 ± 7.9 79.7 ± 4.8 74.2 ± 7.8 | 18.4 ± 9.9 11.3 ± 7.6 16.4 ± 10.6 | 29.3 ± 5.1 28.5 ± 4.2 29.1 ± 4.5 | 7.63 ± 1.37 6.01 ± 0.49 7.12 ± 1.57 | 21.81 ± 6.16 24.94 ± 4.31 26.04 ± 5.04 |
Biessels,2021 [41] | Netherland | lina: 1618 glim: 1545 | lina: 1002/616 glim: 958/587 | 40 | 64.4 ± 9.1 64.4 ± 9.3 | 7.7 ± 6.2 7.4 ± 5.9 | 30.8 ± 5.0 30.7 ± 4.9 | 7.1 ± 0.5 7.1 ± 0.6 | 28.5 ± 1.7 28.5 ± 1.7 |